CLINICAL TRIALS PROFILE FOR NAPHAZOLINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for naphazoline hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00769886 ↗ | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. | Completed | Bausch & Lomb Incorporated | Phase 3 | 2008-10-01 | The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis. |
| NCT00770133 ↗ | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. | Completed | Bausch & Lomb Incorporated | Phase 3 | 2010-02-01 | The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis. |
| NCT01533220 ↗ | Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal | Completed | EMS | Phase 3 | 2013-01-01 | The common cold is a major cause of nasal obstruction and reaches children and adults two or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of the treatment. The study has parallel distribution design, with two equal groups, in which one group will be treated by a combination of naphazoline hydrocloride + pheniramine maleate + panthenol and the other will receive treatment with naphazoline hydrocloride. |
| NCT03324113 ↗ | Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | Active, not recruiting | Sanofi | Phase 1 | 2017-10-17 | Primary Objective: - To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors. Secondary Objectives: - To characterize the overall safety profile of SAR408701 monotherapy. - To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites. - To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part. - To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity. - To assess the potential immunogenicity of SAR408701. |
| NCT05470868 ↗ | Ssafety and Tolerability of PRO-185 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | Phase 1 | 2022-08-01 | Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for naphazoline hydrochloride
Condition Name
Clinical Trial Locations for naphazoline hydrochloride
Trials by Country
Clinical Trial Progress for naphazoline hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for naphazoline hydrochloride
Sponsor Name
